To identify the differential expression of aGalcer/IL-2 treated T cells (iNKT) from human peripheral blood mononuclear cells of healthy donors (HD), chronic hepatitis B (CHB) and HBV-infected hepatocellular cacinoma (HCC) patients

To identify the different status of iNKT cells treated by aGalcer/IL-2 from CHB and HCC patients compared to HD. We enriched α-GalCer/IL-2 expanded iNKT cells from healthy donors (HD iNKT), CHB patients (CHB iNKT), and HBV-infected HCC patients (HCC iNKT) to rperforme next-generation sequencing (NGS). Illumina mRNA-seq sample preparation kit was used to perform paired-end library sequencing with Illumina HiSeq 2000 and sequence analysis was determined using the Illumina data analysis pipeline. Based on the comparison results，we performed the GO and KEGG pathway enrichment analysis. That might suggest the different status of iNKT cells treated by aGalcer/IL-2 between HD, CHB and HBV-infected HCC patients. Differential gene expression between iNKT cells treated by aGalcer/IL-2 from HD, CHB and HBV-infected HCC patients.